Sansure Biotech (SHA:688289) received a medical device registration certificate from China's National Medical Products Administration for its nucleic acid detection kits for COVID-19, influenza A and B, and respiratory syncytial virus, according to a Thursday disclosure to the Shanghai bourse.
The kit is the company's first approved lyophilized nucleic acid detection reagent for respiratory infections, Sansure said in its filing.